Coherus Oncology, Inc. Cost of Revenue
Coherus Oncology, Inc. (CHRS) reported Cost of Revenue of $4.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Coherus Oncology, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $4.24M, a 24.95% increase year-over-year.
- Coherus Oncology, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $3.81M, a 43.76% increase year-over-year.
- Coherus Oncology, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $4.04M, a 47.09% increase year-over-year.
- Coherus Oncology, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $3.72M, a 36.35% increase year-over-year.
- Coherus Oncology, Inc. cost of goods and services sold for fiscal 2025 was $13.81M, a 58.29% increase from fiscal 2024.
- Coherus Oncology, Inc. cost of goods and services sold for fiscal 2024 was $8.73M.
- Coherus Oncology, Inc. cost of goods and services sold for fiscal 2022 was $70.08M, a 21.69% increase from fiscal 2021.
- Coherus Oncology, Inc. cost of goods and services sold for fiscal 2021 was $57.59M, a 52.90% increase from fiscal 2020.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.24M 10-Q · filed 2026-08-05 | $8.06M 10-Q · filed 2026-08-05 | $12.10M derived: sum of 3 quarters · filed 2026-08-05 | $15.82M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $3.81M 10-Q · filed 2026-05-11 | $7.86M derived: sum of 2 quarters · filed 2026-05-11 | $11.58M derived: sum of 3 quarters · filed 2026-05-11 | $14.97M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.77M derived: sum of 2 quarters · filed 2026-03-09 | $11.16M derived: sum of 3 quarters · filed 2026-08-05 | $13.81M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $3.72M 10-Q · filed 2025-11-06 | $7.12M derived: sum of 2 quarters · filed 2026-08-05 | $9.77M 10-Q · filed 2025-11-06 | $12.52M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $3.40M 10-Q · filed 2026-08-05 | $6.05M 10-Q · filed 2026-08-05 | $8.80M derived: sum of 3 quarters · filed 2026-08-05 | $11.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $2.65M 10-Q · filed 2026-05-11 | $5.40M derived: sum of 2 quarters · filed 2026-05-11 | $8.13M derived: sum of 3 quarters · filed 2026-05-11 | $9.94M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.48M derived: sum of 2 quarters · filed 2026-03-09 | $7.29M derived: sum of 3 quarters · filed 2026-03-09 | $8.73M 10-K · filed 2026-03-09 | $117.55M 10-K · filed 2025-03-17 | |||
| 2024-09-30 | $2.73M 10-Q · filed 2025-11-06 | $20.74M 10-Q · filed 2024-11-06 | $4.54M derived: sum of 2 quarters · filed 2025-11-06 | $5.98M 10-Q · filed 2025-11-06 | $83.69M 10-Q · filed 2024-11-06 | -$68.01M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.81M 10-Q · filed 2025-08-07 | $28.37M 10-Q · filed 2024-08-08 | $3.25M 10-Q · filed 2025-08-07 | $62.95M 10-Q · filed 2024-08-08 | -$70.74M derived: sum of 3 quarters · filed 2025-11-13 | -$38.04M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-12 | $34.59M 10-Q · filed 2024-05-09 | -$72.55M derived: sum of 2 quarters · filed 2025-11-13 | -$39.84M derived: sum of 3 quarters · filed 2025-11-13 | -$15.00M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2023-12-31 | -$73.99M derived: 8-K 12 month − 10-Q 9 month · filed 2025-11-13 | -$41.28M derived: sum of 2 quarters · filed 2025-11-13 | -$16.44M derived: sum of 3 quarters · filed 2025-11-13 | $438.00K 8-K · filed 2025-11-13 | $158.99M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $32.70M 10-Q · filed 2024-11-06 | $57.55M derived: sum of 2 quarters · filed 2024-11-06 | $74.42M 10-Q · filed 2024-11-06 | $88.63M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $24.85M 10-Q · filed 2024-08-08 | $41.72M 10-Q · filed 2024-08-08 | $55.92M derived: sum of 3 quarters · filed 2025-03-17 | $91.16M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $16.87M 10-Q · filed 2024-05-09 | $31.08M derived: sum of 2 quarters · filed 2025-03-17 | $66.31M derived: sum of 3 quarters · filed 2025-03-17 | $77.59M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | $14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $49.44M derived: sum of 2 quarters · filed 2025-03-17 | $60.71M derived: sum of 3 quarters · filed 2025-03-17 | $70.08M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $35.23M 10-Q · filed 2023-11-06 | $46.51M derived: sum of 2 quarters · filed 2023-11-06 | $55.88M 10-Q · filed 2023-11-06 | $67.98M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-06-30 | $11.28M 10-Q · filed 2023-08-02 | $20.65M 10-Q · filed 2023-08-02 | $32.75M derived: sum of 3 quarters · filed 2024-03-15 | $54.03M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-03-31 | $9.37M 10-Q · filed 2023-05-08 | $21.47M derived: sum of 2 quarters · filed 2024-03-15 | $42.75M derived: sum of 3 quarters · filed 2024-03-15 | $59.45M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2021-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $33.38M derived: sum of 2 quarters · filed 2024-03-15 | $50.08M derived: sum of 3 quarters · filed 2024-03-15 | $57.59M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $21.28M 10-Q · filed 2022-11-08 | $37.98M derived: sum of 2 quarters · filed 2022-11-08 | $45.49M 10-Q · filed 2022-11-08 | $57.16M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-06-30 | $16.70M 10-Q · filed 2022-08-04 | $24.21M 10-Q · filed 2022-08-04 | $35.88M derived: sum of 3 quarters · filed 2023-03-06 | $44.88M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-03-31 | $7.51M 10-Q · filed 2022-05-05 | $19.18M derived: sum of 2 quarters · filed 2023-03-06 | $28.18M derived: sum of 3 quarters · filed 2023-03-06 | $38.32M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | $11.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $20.67M derived: sum of 2 quarters · filed 2023-03-06 | $30.81M derived: sum of 3 quarters · filed 2023-03-06 | $37.67M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $9.00M 10-Q · filed 2021-11-08 | $19.14M derived: sum of 2 quarters · filed 2021-11-08 | $25.99M 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $10.14M 10-Q · filed 2021-08-05 | $16.99M 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $6.86M 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $17.08M 10-K · filed 2022-02-23 | |||||||
| 2019-06-30 | $601.00K 10-Q · filed 2019-08-05 | $2.83M 10-Q · filed 2019-08-05 | ||||||
| 2019-03-31 | $2.23M 10-Q · filed 2019-05-09 | |||||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |